GSK: ViiV submits application for monthly HIV treatment
(CercleFinance.com) - GSK's ViiV Healthcare has submitted a regulatory application to the European Medicines Agency for cabotegravir to be used in combination with Janssen's rilpivirine as the first monthly, injectable treatment for HIV.
The HIV specialist firm which is owned by GSK, Pfizer and Japan's Shionogi, today announced the submission of a marketing authorisation application to the EMA.
The investigational drug would be used in combination with Janssen's once-monthly, injectable rilpivirine to treat HIV-1 infection in adults, ViiV said.
The application also includes data for cabotegravir oral tablets, intended for use prior to the commencement of injectable therapy.
The move could potentially change the frequency of therapy from 365 days per year for oral, 3-drug regimens taken every day to just 12 shots.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The HIV specialist firm which is owned by GSK, Pfizer and Japan's Shionogi, today announced the submission of a marketing authorisation application to the EMA.
The investigational drug would be used in combination with Janssen's once-monthly, injectable rilpivirine to treat HIV-1 infection in adults, ViiV said.
The application also includes data for cabotegravir oral tablets, intended for use prior to the commencement of injectable therapy.
The move could potentially change the frequency of therapy from 365 days per year for oral, 3-drug regimens taken every day to just 12 shots.
Copyright (c) 2019 CercleFinance.com. All rights reserved.